Journal of International Oncology››2020,Vol. 47››Issue (8): 501-504.doi:10.3760/cma.j.cn371439-20190603-00065
• Short Essays •Previous ArticlesNext Articles
Received:2019-06-03Revised:2020-02-15Online:2020-08-08Published:2020-10-22
"
| 组别 | 性别 | 淋巴结转移程度 | 初诊TNM分期 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 男 | 女 | N0 | N1 | N2 | Ⅱ期 | Ⅲ期 | |||||
| 试验组(n=40) | 21(52.5) | 19(47.5) | 26(65.0) | 10(25.0) | 4(10.0) | 26(65.0) | 14(35.0) | ||||
| 对照组(n=40) | 22(55.0) | 18(45.0) | 26(65.0) | 11(27.5) | 3(7.5) | 26(65.0) | 14(35.0) | ||||
| χ2值 | 0.050 | 0.191 | <0.001 | ||||||||
| P值 | 0.823 | 0.909 | >0.999 | ||||||||
"
| 组别 | 高热 | 呕吐 | 腹痛 | 腹泻 | 肠梗阻 | 切口感染 | 吻合口瘘 |
|---|---|---|---|---|---|---|---|
| 试验组(n=40) | 4(10.0) | 4(10.0) | 6(15.0) | 1(2.5) | 0(0) | 1(2.5) | 1(2.5) |
| 对照组(n=40) | 5(12.5) | 4(10.0) | 5(12.5) | 3(7.5) | 1(2.5) | 2(5.0) | 0(0) |
| χ2值 | - | - | 0.105 | - | - | - | - |
| P值 | >0.999 | >0.999 | 0.745 | 0.615 | >0.999 | >0.999 | >0.999 |
"
| 组别 | CEA(ng/ml) | CA199(μg/ml) | WBC(109个/L) | RBC(1012个/L) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 术前 | 术后 | 术前 | 术后 | 术前 | 术后 | 术前 | 术后 | ||||||||||||||||
| 试验组(n=40) | 17.90±8.31 | 7.93±1.18a | 23.91±6.04 | 9.95±1.78a | 5.99±0.53 | 9.36±1.18 | 4.47±0.27 | 4.00±0.31 | |||||||||||||||
| 对照组(n=40) | 20.09±8.94 | 15.01±5.41a | 25.29±6.64 | 14.22±2.39a | 6.81±0.65 | 10.50±1.22 | 4.46±0.27 | 3.98±0.25 | |||||||||||||||
| t值 | -0.346 | -2.500 | -0.300 | -2.790 | -1.898 | -1.326 | 0.041 | 0.122 | |||||||||||||||
| P值 | 0.731 | 0.016 | 0.765 | 0.007 | 0.061 | 0.189 | 0.968 | 0.903 | |||||||||||||||
| 组别 | PLT(109个/L) | ALT(U/L) | 血肌酐(μmol/L) | ||||||||||||||||||||
| 术前 | 术后 | 术前 | 术后 | 术前 | 术后 | ||||||||||||||||||
| 试验组(n=40) | 213.02±23.50 | 259.18±29.36 | 18.25±4.17 | 14.48±2.14 | 70.77±5.88 | 64.48±5.63 | |||||||||||||||||
| 对照组(n=40) | 225.94±33.87 | 266.97±35.79 | 17.35±5.60 | 16.40±3.52 | 69.20±5.17 | 65.09±5.45 | |||||||||||||||||
| t值 | -0.614 | -0.332 | 0.129 | -0.467 | 0.394 | -0.101 | |||||||||||||||||
| P值 | 0.541 | 0.741 | 0.898 | 0.642 | 0.694 | 0.920 | |||||||||||||||||
| [1] | 中华人民共和国国家卫生和计划生育委员会医政医管局, 中华医学会肿瘤学分会. 中国结直肠癌诊疗规范(2017年版)[J]. 中国实用外科杂志, 2018, 38(10): 1089-1103. 3-23. DOI: 10.19538/j.cjps.issn1005-2208.2018.10.01. |
| [2] | 中国医师协会结直肠肿瘤专委会腹膜肿瘤专业委员会. 结直肠癌腹膜转移诊治中国专家意见(2017)[J]. 中华结直肠疾病电子杂志, 2017,6(5):360-366. DOI: 10.3877/cma.j.issn.2095-3224.2017.05.002. |
| [3] | Cunningham D, Atkin W, Lenz HJ, et al. Colorectal cancer[J]. Lancet, 2010,375(9719):1030-1047. DOI: 10.1016/S0140-6736(10)60353-4. doi:10.1016/S0140-6736(10)60353-4pmid:20304247 |
| [4] | Franko J, Shi Q, Goldman CD, et al. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase Ⅲ trials N9741 and N9841[J]. J Clin Oncol, 2012,30(3):263-267. DOI: 10.1200/JCO.2011.37.1039. doi:10.1200/JCO.2011.37.1039 |
| [5] | Yonemura Y, Bandou E, Kawamura T, et al. Quantitative prognostic indicators of peritoneal dissemination of gastric cancer[J]. Eur J Surg Oncol, 2006,32(6):602-606. DOI: 10.1016/j.ejso.2006.03.003. pmid:16617004 |
| [6] | Koppe MJ, Boerman OC, Oyen WJ, et al. Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies[J]. Ann Surg, 2006,243(2):212-222. DOI: 10.1097/01.sla.0000197702.46394.16. doi:10.1097/01.sla.0000197702.46394.16pmid:16432354 |
| [7] | 何振华, 张森, 宋现青, 等. 结直肠癌腹膜种植转移的相关因素分析[J] 中国肿瘤临床, 2013,40(2):107-110. DOI: 10.3969/j.issn.1000-8179.2013.02.012. doi:doi:10.3969/j.issn. 1000-8179.2013.02.012 |
| [8] | Lemmens VE, Klaver YL, Verwaal VJ, et al. Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: a population-based study[J]. Int J Cancer, 2011,128(11):2717-2725. DOI: 10.1002/ijc.25596. doi:10.1002/ijc.25596pmid:20715167 |
| [9] | Segelman J, Granath F, Holm T. Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer[J]. Br J Surg, 2012,99(5):699-705. DOI: 10.1002/bjs.8679. pmid:22287157 |
| [10] | Elias D, Glehen O, Pocard M, et al. A comparative study of complete cytoreductive surgery plus intraperitoneal chemotherapy to treat peritoneal dissemination from colon, rectum, small bowel, and nonpseudomyxoma appendix[J]. Ann Surg, 2010,251(5):896-901. DOI: 10.1097/SLA.0b013e3181d9765d. doi:10.1097/SLA.0b013e3181d9765dpmid:20395843 |
| [11] | Turaga K, Levine E, Barone R, et al. Consensus guidelines from the American society of peritoneal surface malignancies on standar-dizing the delivery of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer patients in the United States[J]. Ann Surg Oncol, 2014,21(5):1501-1505. DOI: 10.1245/s10434-013-3061-z. doi:10.1245/s10434-013-3061-z |
| [12] | Votanopoulos KI, Swett K, Blackham AU, et al. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from rectal cancer[J]. Ann Surg Oncol, 2013,20(4):1088-1092. DOI: 10.1245/s10434-012-2787-3. doi:10.1245/s10434-012-2787-3 |
| [13] | Sato H, Kotake K, Sugihara K, et al. Clinicopathological factors associated with recurrence and prognosis after R0 resection for stage Ⅳ colorectal cancer with peritoneal metastasis[J]. Dig Surg, 2016,33(5):382-391. DOI: 10.1159/000444097. doi:10.1159/000444097pmid:27119565 |
| [14] | Glehen O, Cotte E, Schreiber V, et al. Intraperitoneal chemohyperthermia and attempted cytoreductive surgery in patients with peritoneal carcinomatosis of colorectal origin[J]. Br J Surg, 2004,91(6):747-754. DOI: 10.1002/bjs.4473. pmid:15164446 |
| [15] | 锁涛, 童汉兴, 万柳华, 等. 中国大陆腹腔热灌注化疗治疗胃肠癌腹膜转移癌的现状[J]. 中国肿瘤临床, 2012,39(22):1754-1756. DOI: 10.3969/j.issn.1000-8179.2012.22.016. doi:doi:10.3969/j.issn.1000-8179.2012.22.016 |
| [16] | 宋文灿, 潘明, 徐金发, 等. 雷替曲塞联合奥沙利铂在结直肠癌一线治疗失败后的临床应用[J]. 安徽医学, 2014,35(5):641-644. DOI: 10.3969/j.issn.1000-0399.2014.05.029. |
| [17] | Oliphant R, Horgan PG, Morrison DS, et al. Validation of a modified clinical risk score to predict cancer-specific survival for stage Ⅱ colon cancer[J]. Cancer Med, 2015,4(1):84-89. DOI: 10.1002/cam4.352. doi:10.1002/cam4.352pmid:25487740 |
| [18] | Tanner EJ, Black DR, Zivanovic O, et al. Patterns of first recu-rrence following adjuvant intraperitoneal chemotherapy for stage ⅢC ovarian cancer[J]. Gynecol Oncol, 2012,124(1):59-62. DOI: 10.1016/j.ygyno.2011.09.011. pmid:21982046 |
| [19] | 张微, 邹玺, 胡玥, 等. 雷替曲塞联合伊立替康与FOLFIRI方案二线治疗晚期结直肠癌的近期疗效[J]. 现代肿瘤医学, 2015,23(11):1550-1552. DOI: 10.3969/j.issn.1672-4992.2015.11.22. |
| [20] | Li L, Huang XE. Thalidomide combined with chemotherapy in treating patients with advanced lung cancer[J]. Asian Pac J Cancer Prev, 2016,17(5):2583-2585. pmid:27268634 |
| [21] | 赵海波, 李胜范. 大肠癌根治术后静脉化疗联合腹腔化疗疗效分析[J]. 当代医学, 2009,15(1):80-81. DOI: 10.3969/j.issn.1009-4393.2009.01.059. |
| [22] | Zhao P, Ding Z, Tang L, et al. Preliminary investigation of intra-peritoneal raltitrexed in patients with gastric cancer[J]. World J Surg Oncol, 2014,12:403. DOI: 10.1186/1477-7819-12-403. doi:10.1186/1477-7819-12-403pmid:25547003 |
| [23] | 胡军, 段浩清, 罗俊峰, 等. 雷替曲塞术中腹腔灌注化疗对结直肠癌的安全性和近期疗效研究[J]. 中国医学创新, 2018,15(31):17-20. DOI: 10.3969/j.issn.1674-4985.2018.31.005. |
| No related articles found! |
| Viewed | ||||||
| Full text |
|
|||||
| Abstract |
|
|||||
